Veterinary research communications · 2026
Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Xianhai, Zhu Guangshan, Dai Yindi, Zhang Gang, Wan Jin, Zhang Shaonan, Tu Jiahui, Hu Wenjun, Ma Nini, Dong Yuexin, Wang Cong, Qiu Zhixia
Аннотация
BACKGROUND: Tylvalosin (acetylisovaleryltylosin), a breakthrough semi-synthetic derivative of tylosin engineered to address pharmacokinetic limitations and bacterial resistance, exhibits dual therapeutic efficacy against porcine reproductive and PRRSV-associated pneumonia and mycoplasma infections in swine. Limited research has yet to investigate pharmacokinetic profiles of tylvalosin and its metabolites. This study, therefore, aims to pioneer a robust UPLC-MS/MS method for simultaneous quantification of tylvalosin and its key bioactive metabolites, desmycosin 3-acetate and tylosin 3-acetate, in swine plasma and tissues, and to investigate the pharmacokinetic properties of different tylvalosin formulations.
RESULTS: A robust UPLC-MS/MS method was developed and validated, showing excellent performance with good linearity, low deviation, high accuracy, minimal carry-over and matrix effects, as well as favorable stability under various conditions. Pharmacokinetic analysis following intravenous (i.v.) or intragastric administration in swine revealed that formulation I outperformed other formulations, exhibiting the highest bioavailability (F, 57.32%), the longest elimination half-life (t1/2, 7.93 h), and a delayed time to maximum plasma concentration (tmax, 3.14 h). Dose-normalized metabolites exposures were also significantly higher for formulation I compared to other formulations. Critically, tylvalosin and its metabolites preferentially accumulated in pulmonary and lymphatic tissues at 48 h post-administration, indicating rapid absorption, swift metabolism, and slow elimination.
CONCLUSIONS: The findings confirm the optimized therapeutic potential of tylvalosin, particularly formulation I, supported by its favorable pharmacokinetic profile and tissue distribution. This study establishes a new standard for veterinary PK-PD research and provides a PK evidence-based formulation optimization approaches to enhance treatment efficacy.
RESULTS: A robust UPLC-MS/MS method was developed and validated, showing excellent performance with good linearity, low deviation, high accuracy, minimal carry-over and matrix effects, as well as favorable stability under various conditions. Pharmacokinetic analysis following intravenous (i.v.) or intragastric administration in swine revealed that formulation I outperformed other formulations, exhibiting the highest bioavailability (F, 57.32%), the longest elimination half-life (t1/2, 7.93 h), and a delayed time to maximum plasma concentration (tmax, 3.14 h). Dose-normalized metabolites exposures were also significantly higher for formulation I compared to other formulations. Critically, tylvalosin and its metabolites preferentially accumulated in pulmonary and lymphatic tissues at 48 h post-administration, indicating rapid absorption, swift metabolism, and slow elimination.
CONCLUSIONS: The findings confirm the optimized therapeutic potential of tylvalosin, particularly formulation I, supported by its favorable pharmacokinetic profile and tissue distribution. This study establishes a new standard for veterinary PK-PD research and provides a PK evidence-based formulation optimization approaches to enhance treatment efficacy.